Please assess the completion status of the following clinical trial:

Trial Title: Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening~2. Active UC confirmed by endoscopy~Exclusion criteria:~1. Severe extensive colitis~2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD~3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etrasimod 2 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).